Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

 
• By Joseph Haas, Ian Haydock, and Anju Ghangurde

Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.

DealWatch_1200x675

More from Deals

More from Business